Your shopping cart is currently empty

Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled form of Ponesimod. It is an effective, selective, and orally active agonist of S1P1, with an IC50 value of 6 nM in radioligand binding assays. Ponesimod-d7 efficiently activates S1P1-mediated signal transduction with an EC50 of 5.7 nM and can prevent lymphocyte-mediated tissue inflammation.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled form of Ponesimod. It is an effective, selective, and orally active agonist of S1P1, with an IC50 value of 6 nM in radioligand binding assays. Ponesimod-d7 efficiently activates S1P1-mediated signal transduction with an EC50 of 5.7 nM and can prevent lymphocyte-mediated tissue inflammation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.